Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (7211)	3/30/2005 9:18:19 AM
From: ACAN	Read Replies (1) \| Respond to of 23958

Ken; DFIB biz.yahoo.com Press Release Source: Cardiac Science, Inc. Cardiac Science Awarded Contract With Novation Wednesday March 30, 1:30 am ET - Group Purchasing Organization Serves 2,300 Healthcare Facilities Nationwide IRVINE, Calif., March 30 /PRNewswire-FirstCall/ -- Cardiac Science, Inc. (Nasdaq: DFIB - News), a leading manufacturer of automatic external defibrillators, today announced that it has been awarded a contract from Novation, the supply company of VHA Inc. and the University HealthSystem Consortium (UHC), covering Cardiac Science's patented Powerheart® Cardiac Rhythm Module® (CRM®) a fully-automatic therapeutic bedside monitor-defibrillator designed for medically-supervised environments such as hospitals, outpatient medical clinics and physician offices. The contract, which was established under Novation's new technology program, offers access to this innovative product to 2,300 VHA and UHC acute and non-acute healthcare facilities located throughout the United States. Powerheart CRM is the only FDA-cleared therapeutic bedside defibrillator- monitor on the market that is designed to be prophylactically attached to at-risk cardiac patients, continuously monitor their heart rhythms and when clinically appropriate, automatically and instantly provide lifesaving defibrillation therapy without the need to wait for intervention by a nurse or physician. Cardiac Science Chairman and CEO Raymond W. Cohen said, "The Novation contract provides us with access to a large group of hospitals and increases awareness of the Powerheart CRM technology among administrators and other decision makers. As clinical evidence mounts that suggests this technology may dramatically increase survival rates of at-risk cardiac patients and potentially reduce hospitalization costs, we believe that we may achieve greater penetration in the U.S. hospital market. " ------------------------------------------------------------- Ken - I think this whole concept of automatic defibrillation has long term merit, because of the removal of time factor delay, cost effective per intervention(as per personnel involved), and overall cost of simple defibrillators, which allows them to be placed on all patients who might have a cardiac event occur(even if transient). Many more patients will survive, I believe, as compared to a crash cart routine. This may become a routine installation in all healthcare facilities. Allan